Last reviewed · How we verify
Low Dose Acetazolamide
Acetazolamide inhibits carbonic anhydrase to reduce bicarbonate reabsorption in the kidney, promoting diuresis and alkalinizing urine while lowering intraocular pressure.
Acetazolamide inhibits carbonic anhydrase to reduce bicarbonate reabsorption in the kidney, promoting diuresis and alkalinizing urine while lowering intraocular pressure. Used for Open-angle glaucoma, Altitude sickness prevention and treatment, Ocular hypertension.
At a glance
| Generic name | Low Dose Acetazolamide |
|---|---|
| Also known as | Diamox |
| Sponsor | University of Utah |
| Drug class | Carbonic anhydrase inhibitor |
| Target | Carbonic anhydrase II |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology; Pulmonology |
| Phase | FDA-approved |
Mechanism of action
Acetazolamide is a carbonic anhydrase inhibitor that decreases aqueous humor production in the eye and increases renal bicarbonate excretion, leading to mild metabolic acidosis. At low doses, it is used primarily to reduce intraocular pressure in glaucoma and to prevent or treat altitude sickness by promoting respiratory alkalosis and diuresis.
Approved indications
- Open-angle glaucoma
- Altitude sickness prevention and treatment
- Ocular hypertension
Common side effects
- Paresthesia (tingling in extremities)
- Altered taste (especially carbonated beverages)
- Mild diuresis
- Metabolic acidosis
- Fatigue
Key clinical trials
- Stent Implantation Versus Medical Therapy for Idiopathic IntracraniaL Hypertension (SIMPLE) (PHASE3)
- Optimal Dosage of Acetazolamide for OSA Treatment (PHASE4)
- Diuretic Treatment in Acute Heart Failure With Volume Overload Guided by Serial Spot Urine Sodium Assessment (PHASE4)
- RePOSA-Revealing the Efficacy of IHL-42X Use in Patients With OSA (PHASE2, PHASE3)
- Rivaroxaban vs. Warfarin in CVT Treatment (PHASE3)
- Surgical Idiopathic Intracranial Hypertension Treatment Trial (PHASE3)
- Quantitative D-dimer Level and Anticoagulant Therapy in Idiopathic Intracranial Hypertension (EARLY_PHASE1)
- Acetazolamide and Spironolactone to Increase Natriuresis in Congestive Heart Failure (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Low Dose Acetazolamide CI brief — competitive landscape report
- Low Dose Acetazolamide updates RSS · CI watch RSS
- University of Utah portfolio CI